Reading the tape
NASDAQ: IBIO
iBio, Inc.
Healthcare · Biotechnology
Data caution
Per-share valuation inputs need verification
Event dated Dec 31, 2025Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Market Cap
$26.68M
52w High
$3.82
52w Low
$0.56
P/E
-6.77
Volume
2.97M
Outstanding Shares
15.79M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 59.43%Revenue (TTM): -20%FCF (TTM): -17.7%
What changed
The stock rose 59.43% over the last year. Revenue declined 20% over the trailing twelve months. Operating margin moved from -4,149.33% to -7,657.67%. Free cash flow declined 17.7% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -7,657.67%. A decisive move in revenue — currently down 20% — would be the clearest signal to resolve the ambiguity.
Company profile
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States.
CEOMartin Brenner
SectorHealthcare
IndustryBiotechnology
Employees16
IPO dateAug 19, 2008
Valuation
Forward P/E—
EV/EBITDA-0.17
Enterprise value$2.94M
Stock splits
Nov 29, 2023↓ Reverse
Every 20 shares became 1
Oct 10, 2022↓ Reverse
Every 25 shares became 1
Jun 11, 2018↓ Reverse
Every 10 shares became 1
Profitability & growth
Revenue growth-100%
Gross margin-76.67%▲0.00%vs FY2024
Operating margin-7,657.67%▲37.09%vs FY2024
ROE-123.5%▼5.74%vs FY2024
Analyst consensus
RatingBuy
Target price$2.80▲65.68%
3
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 1, 2026
Q2 FY26 · EPS est -$0.06 · Revenue est $20K
View